Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit-Reference-Cited by-同舟云学术

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

Published:2021-10-18 Issue: Volume: Page:
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Nickles Emily,Dharmadhikari Bhushan,Yating Li,Walsh Robert J.,Koh Liang Piu,Poon Michelle,Tan Lip Kun,Wang Ling-Zhi,Ang Yvonne,Asokumaran Yugarajah,Chong Wan Qin,Huang Yiqing,Loh Kwok Seng,Tay Joshua,Soo Ross,Koh Mickey,Ho Liam Pock,Chan Marieta,Niam Madelaine,Soh Melissa,Luah Yen Hoon,Lim Chwee Ming,Kaliaperumal Nivashini,Au Veonice B.,Talib Najwa Binte Said Nasir,Sng Reina,Connolly John E.,Goh Boon Cher,Schwarz Herbert

Funder

National Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-021-03075-3.pdf

Reference65 articles.

1. Smith C, Khanna R (2012) A new approach for cellular immunotherapy of nasopharyngeal carcinoma. Oncoimmunology 1(8):1440–1442

2. Tsao SW, Tsang CM, and Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732).

3. Petersson F (2015) Nasopharyngeal carcinoma: a review. Semin Diagn Pathol 32(1):54–73